Amyloid plaque imaging from IMPY/SPECT to AV-45/PET

Chang Gung Medical Journal

Volumn 35, Issue 3, 2012, Pages 211-218

  Kung, Mei Ping ^a,b   Weng, Chi Chang ^c   Lin, Kun Ju ^a   Hsiao, Ing Tsung ^a   Yen, Tzu Chen ^a   Wey, Shiaw Pyng ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Alzheimer's disease; AV 138; AV 45; IMPY; amyloid plaques

Indexed keywords

4 ((4 (2 (2 (2 FLUOROETHOXY)ETHOXY)ETHOXY)PHENYL)ETHYNYL) N METHYLBENZENAMINE; 4 [2 (6 (2 (2 (2 FLUOROETHOXYETHOXY)ETHOXY)PYRIDIN 3 YL)VINYL)] N METHYLBENZENAMINE F 18; AMYLOID BETA PROTEIN; AV 138; AV 45; IODINE 2,3 DIHYDRO 1H IMIDAZO[1,2 B]PYRAZOLE I 123; IODINE 2,3 DIHYDRO 1H IMIDAZO[1,2 B]PYRAZOLE I 125; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; CLINICAL EVALUATION; DISEASE MARKER; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG SAFETY; DRUG STRUCTURE; EARLY DIAGNOSIS; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; MOLECULAR PATHOLOGY; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ANALYSIS;

EID: 84863540070     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: 10.4103/2319-4170.106151     Document Type: Review

References (26)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6.
2. Selkoe DJ. Imaging Alzheimer's amyloid. Nat Biotechnol 2000;18:823-4.
3. Thorsett ED, Latimer LH. Therapeutic approaches to Alzheimer's disease. Curr Opin Chem Biol 2000;4:377-82.
4. Vickers JC, Dickson TC, Adlard PA, Saunders HL, King CE, McCormack G. The cause of neuronal degeneration in alzheimer's disease. Prog Neurobiol 2000;60:139-65.
5. Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001;76:173-81.
6. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. Immunization with amyloid-b attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7.
7. Kung MP, Hou C, Zhuang ZP, Zhang B, Skovronsky D, Trojanowski JQ, Lee VM, Kung HF. IMPY: An improved thioflavin-T derivative for in vivo labeling of b-amyloid plaques. Brain Res 2002;956:202-10.
8. Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Res 2004;1025:89-105.
9. Kung MP, Hou C, Zhuang ZP, Cross AJ, Maier DL, Kung HF. Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice. Eur J Nucl Med Mol Imaging 2004;31: 1136-45.
10. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloidbeta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005;25:10598-606.
11. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, Staufenbiel M, Iwata N, Ono M, Saido TC, Suzuki K, Mori H, Higuchi M, Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 2007;27:10957-68.
12. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrém M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55: 306-19.
13. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Långström B, Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-65.
14. Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F-18 stilbenes as PET imaging agents for detecting β-amyloid plaques in the brain. J Med Chem 2005;48:5980-8.
15. Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F-18 PEG stilbenes as PET imaging agents targeting Aβ aggregates in the brain. Nucl Med Biol 2005;32:799-809.
16. Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, Itoh M, Iwata R, Yanai K, Arai H. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro] ethoxy) benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 2007;48:553-61.
17. 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med 2009;50:818-22.
18. 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009;50:1251-9.
19. 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience. Q J Nucl Med Mol Imaging 2009;53:387-93.
20. Chandra R, Oya S, Kung MP, Hou C, Jin LW, Kung HF. New diphenylacetylenes as probes for positron emission tomographic imaging of amyloid plaques. J Med Chem 2007;50:2415-23.
21. 18F-labeled biphenylalkyne as a positron emission tomography imaging agent for β-amyloid plaques. Nucl Med Biol 2009;36:411-7.
22. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-35.
23. 18F-AV-45: a PET agent for Aβ plaques in the brain. J Nucl Med 2009;50:1887-94.
24. 18F PET amyloid-imaging agents: Preclinical to clinical correlations. J Nucl Med 2008;49:34p.
25. 18F]AV-45 (Florbetapir F 18) for imaging β-amyloid plaques in human brain. Appl Radiat Isot 2010;68:2293-7.
26. 18F]AV-45, a novel amyloid imaging agent-a pilot study. Nucl Med Biol 2010;37:497-508.